THE IMPACT OF A MEDICATION PROFILE RELEASE PROGRAM ON OUTPATIENT DRUG USE: AN EVALUATION OF SASKATCHEWAN'S PATIENT PROFILE RELEASE PROGRAM
Date
1996
Authors
Journal Title
Journal ISSN
Volume Title
Publisher
ORCID
Type
Degree Level
Masters
Abstract
The Patient Profile Release Program was designed to promote optimal drug use in Saskatchewan by identifying individuals who are at risk for drug-related problems and communicating these drug use concerns to the physicians and pharmacists responsible for their care. During 1992, the PPRP had three components — the Extreme User, Polypharmacy and Polyprescriber Programs — which monitored for the use of high dosages of mood- modifying drugs and asthma medications, the use of multiple different drugs and the use of multiple prescribers, respectively. Similar programs have been implemented elsewhere; however, there is little objective evidence that these programs effectively influence physician prescribing practices and improve patient drug use.
The objectives of the present investigation were to describe the individuals who were identified by the PPRP in 1992, evaluate the impact of the PPRP on drug use by these patients and describe the use of mood-modifying drugs and asthma medications in the province of Saskatchewan. An historical cohort study with a 3.5 month follow-up period was used to evaluate the impact of the PPRP. The study population included all individuals who had a profile released under the Program during 1992. Profiles for the intervention group subjects were released at the time that they were identified whereas profile release for the comparison group subjects was delayed for at least two months after the index identification. Re-identification by the PPRP was the primary outcome of interest.
During 1992, 3124 individuals were identified by the PPRP, of which 2542 (81%) were eligible for inclusion in this study. 58.7%, 25.1% and 15.3% of the subjects were identified under the ExU, PPh and PPr Programs, respectively. The ExU and PPh subjects tended to be female and elderly. Women were also more likely than men to be identified under the PPr Program.
For all three Program components, the intervention group subjects were significantly less likely than comparison group subjects to be re-identified by the PPRP. This reduction in the likelihood of re-identification persisted even after controlling for differences between the study groups with respect to age, sex, residence, coverage type, the numbers of pharmacies and prescribers during the pre-identification period, hospitalization during the follow-up period, the level of extreme use and the number of different drugs. A long-term descriptive analysis of the intervention group subjects demonstrated that re-identification continued during the 9 month post-intervention period. This finding highlights the need for ongoing feedback.
The findings of the present investigation indicate that the release of patient medication profiles under Saskatchewan's PPRP was associated with a reduction in the risk of re-identification during a short-term follow-up period. Since re-identification is a marker of changes in drug utilization, the findings indicate that profile release was associated with a decreases in the level of drug use, the number of different drugs and the number of different prescribers for individuals identified under the ExU, PPh and PPr Programs, respectively. Given the high threshold criteria for identification under the PPRP, the observed decreases in drug utilization reflect an improvement in the quality of patient drug use.
Description
Keywords
Patient Profile Release Program
Citation
Degree
Master of Science (M.Sc.)
Department
Pharmacy and Nutrition